Revenue left after the direct cost of what is sold
EBITDA margin
33.6%
15.7%
Profit before interest, tax, depreciation and amortization
Operating margin
29.5%
12.1%
Profit from operations, before interest and tax
Net margin
18.5%
7.3%
Profit after every cost and tax
EV/EBITDA
15.2×
13.2×
Enterprise value ÷ EBITDA, profitable companies
EV/Sales
6.2×
2.6×
Enterprise value ÷ revenue
Cost of capital
7.85%
7.08%
Return investors require, debt and equity blended
SG&A ÷ revenue
21.9%
—
Selling, general and administrative costs
Debt ÷ capital
12.7%
—
Share of funding from debt, at market values
Beta (levered / total unlevered)
0.98 / 5.35
—
Market risk / all the risk an undiversified owner carries
Source: Aswath Damodaran, NYU Stern, January 2026. Aggregates: total profit ÷ total revenue across the group, so large companies weigh more.
Frequently asked questions
What is the average profit margin in the pharmaceutical industry?
Across 228 U.S. public companies in the pharmaceutical industry, net profit is 18.5% of revenue, operating profit 29.5% and gross profit 71.7% (January 2026 data from NYU Stern). That gross margin ranks 4 of 94 industries.
What is a good EBITDA margin in the pharmaceutical industry?
The industry average is 33.6%, against 15.7% for the typical industry. A business above 33.6% keeps more of each sale than the listed companies in its field.
What multiple do businesses in the pharmaceutical industry sell for?
Listed companies in the pharmaceutical industry trade at 15.2× EBITDA and 6.2× revenue. Small private businesses sell for far less: U.S. small businesses averaged 2.7× seller’s discretionary earnings in Q2 2026 (BizBuySell).
What discount rate should I use for a business in the pharmaceutical industry?
A diversified investor would want about 7.8% on the whole business (the industry cost of capital). An owner with most of their wealth in it carries more risk: 3.95% + total beta 5.35 × 4.46% = 27.8%.